THIOTEPA GENOPHARM 15 mg, lyophilizate for parenteral use bottle

Link to share

Active ingredients: THIOTÉPA

Commercialized according to BDPMDispensing in France: Prescription only

Lyophilizate for parenteral usebottleintramusculaire;intrapleurale;intrapéricardiaque;intrapéritonéale;intraveineuse;intravésicale

No current ANSM shortage notice is included

Package details

Original BDPM fields are shown in French.

Official name: THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral
Pharmaceutical form: lyophilisat pour usage parentéral
Route of administration: intramusculaire;intrapleurale;intrapéricardiaque;intrapéritonéale;intraveineuse;intravésicale
Presentation description: 1 flacon(s) en verre de 15 mg
Marketing authorisation holder: EFISCIENS (MALTE)
Reimbursement according to BDPM: —
Approval for use in healthcare institutions: oui
Commercialization declaration date: 16 Feb 2006
Prescription and dispensing conditions: Prescription only
List I: prescription-only medicine
Requires special monitoring during treatment
Prescribed by a hospital doctor
Prescribed by specialists only
Original BDPM wording: liste I · médicament nécessitant une surveillance particulière pendant le traitement · prescription hospitalière · prescription réservée aux médecins compétents en CANCEROLOGIE · prescription réservée aux spécialistes et services HEMATOLOGIE · prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE
Enhanced ANSM monitoring: No

BDPM identifiers

CIS64342415CIP75639310CIP133400956393107

Composition in BDPM

Composition in BDPM
Component	Amount per unit	Source type
THIOTÉPAlyophilisat	15 mg · un flacon	SA

Information is based on BDPM data and is for reference only. Consult a doctor before use.

Similar medicines

Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.

The current BDPM data does not list similar medicines for this product.